Published in Women's Health Weekly, April 29th, 2010
Letrozole is indicated for post-menopausal women with hormone-receptor positive breast cancer. It is prescribed off-label for the treatment of infertility, despite being assigned a pregnancy-risk category D by the Food and Drug Administration (FDA), which indicates the drug is associated with human fetal risk.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly